Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sander F Garrelfs

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
The New England Journal of Medicine|November 10, 2021
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. ReplySander F Garrelfs, John M Gansner, John C Lieske
Clinical Kidney Journal|May 20, 2022
Primary hyperoxaluria: the pediatric nephrologist's point of viewEfrat Ben-Shalom, Sander F Garrelfs, Jaap W Groothoff
Journal of Inherited Metabolic Disease|November 24, 2024
Human glyoxylate metabolism revisited: New insights pointing to multi-organ involvement with implications for siRNA-based therapies in primary hyperoxaluriaRonald J A Wanders, Jaap W Groothoff, Lisa J Deesker, et al.
Journal of Inherited Metabolic Disease|January 11, 2024
Glyoxylate reductase: Definitive identification in human liver mitochondria, its importance for the compartment-specific detoxification of glyoxylateSander F Garrelfs, Serhii Chornyi, Heleen Te Brinke, et al.
Brain Injury|January 28, 2015
Return-to-work in patients with acquired brain injury and psychiatric disorders as a comorbidity: A systematic reviewSander F Garrelfs, Birgit H P M Donker-Cools, Haije Wind, et al.
Analytical Chemistry|December 24, 2019
Development and Validation of a New Gas Chromatography-Tandem Mass Spectrometry Method for the Measurement of Enrichment of Glyoxylate Metabolism Analytes in Hyperoxaluria Patients Using a Stable Isotope ProcedureDewi van Harskamp, Sander F Garrelfs, Michiel J S Oosterveld, et al.
Pediatric Nephrology (Berlin, Germany)|October 19, 2022
The retinal phenotype in primary hyperoxaluria type 2 and 3Johannes Birtel, Roselie M Diederen, Philipp Herrmann, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 10, 2023
Plasma oxalate and glycolate concentrations in dialysis patients with and without primary hyperoxaluria type 1Elisabeth L Metry, Sander F Garrelfs, Hessel Peters-Sengers, et al.
Orphanet Journal of Rare Diseases|December 24, 2024
Application of four pricing models for orphan medicines: a case study for lumasiranNoa Rosenberg, Evert Manders, Sibren van den Berg, et al.
Kidney International|October 20, 2023
Corrigendum to "Successful kidney-alone transplantation in a patient with PH1 on combination RNA-interference therapy." Kidney International, 2023;104:203-204Elisabeth L Metry, Lisa J Deesker, Sander F Garrelfs, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
The New England Journal of Medicine|November 10, 2021
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. ReplySander F Garrelfs, John M Gansner, John C Lieske
Clinical Kidney Journal|May 20, 2022
Primary hyperoxaluria: the pediatric nephrologist's point of viewEfrat Ben-Shalom, Sander F Garrelfs, Jaap W Groothoff
Journal of Inherited Metabolic Disease|November 24, 2024
Human glyoxylate metabolism revisited: New insights pointing to multi-organ involvement with implications for siRNA-based therapies in primary hyperoxaluriaRonald J A Wanders, Jaap W Groothoff, Lisa J Deesker, et al.
Journal of Inherited Metabolic Disease|January 11, 2024
Glyoxylate reductase: Definitive identification in human liver mitochondria, its importance for the compartment-specific detoxification of glyoxylateSander F Garrelfs, Serhii Chornyi, Heleen Te Brinke, et al.
Brain Injury|January 28, 2015
Return-to-work in patients with acquired brain injury and psychiatric disorders as a comorbidity: A systematic reviewSander F Garrelfs, Birgit H P M Donker-Cools, Haije Wind, et al.
Analytical Chemistry|December 24, 2019
Development and Validation of a New Gas Chromatography-Tandem Mass Spectrometry Method for the Measurement of Enrichment of Glyoxylate Metabolism Analytes in Hyperoxaluria Patients Using a Stable Isotope ProcedureDewi van Harskamp, Sander F Garrelfs, Michiel J S Oosterveld, et al.
Pediatric Nephrology (Berlin, Germany)|October 19, 2022
The retinal phenotype in primary hyperoxaluria type 2 and 3Johannes Birtel, Roselie M Diederen, Philipp Herrmann, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 10, 2023
Plasma oxalate and glycolate concentrations in dialysis patients with and without primary hyperoxaluria type 1Elisabeth L Metry, Sander F Garrelfs, Hessel Peters-Sengers, et al.
Orphanet Journal of Rare Diseases|December 24, 2024
Application of four pricing models for orphan medicines: a case study for lumasiranNoa Rosenberg, Evert Manders, Sibren van den Berg, et al.
Kidney International|October 20, 2023
Corrigendum to "Successful kidney-alone transplantation in a patient with PH1 on combination RNA-interference therapy." Kidney International, 2023;104:203-204Elisabeth L Metry, Lisa J Deesker, Sander F Garrelfs, et al.
Pageof 3